Advertisement

Topics

Companies Related to "Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom" [Most Relevant Company Matches] RSS

11:14 EDT 15th August 2018 | BioPortfolio

Here are the most relevant search results for "Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom" found in our extensive corporate database of over 50,000 company records.

Showing "Post Authorization Safety Study Biologicals Pandemic Influenza Vaccine" Companies 1–25 of 2,600+

Extremely Relevant

Vaxin Inc.

Vaxin Inc. is a clinical stage biotechnology company, founded in December 1997 with facilities in Rockville, MD and Birmingham, AL, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technol...


Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already...

NexBio Incorporated

In recent years the world has witnessed the outbreak of SARS, the worldwide spread of avian influenza viruses, and the escalating outbreaks of avian influenza viruses in humans. The present unavailability of a vaccine against avian influenza infection in humans is of grave concern. Health authorities worldwide fear an imminent and inevitable influenza pandemic in addition to the more routine but ...


Novavax

Novavax Inc. is a biotechnology company committed to leading the global fight against infectious diseases by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbrea...

Sinovac Biotech Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). PanfluTM, Sinovac's pandemic influenza vaccine (H5N1), has already b...

Seqirus

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.1,2 CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories, and ...

FluGen, Inc.

FluGen, Inc. is a privately held biotechnology company founded in 2005 and based in Madison, WI. The company has been developing novel influenza vaccine technology first invented at the University of Wisconsin-Madison, in the laboratories of Dr. Yoshihiro Kawaoka and Dr. Gabriele Neumann, and exclusively licensed to FluGen by WARF. The REDEE FLU influenza ...

Swiss Vaccine Research Institute

The SVRI is a partnership of five research institutes in Switzerland. The SVRI was created in 2007 in Lausanne and is supported by the Swiss Secretariat of Education and Research. Its primary objective is to develop effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer. SVRI plays an instrument...

FluGen

FluGen is an emerging leader in the fight to boost effectiveness of influenza vaccines and other infectious disease products. The company has differentiating technologies that enable it to create value and compete in the large, rapidly growing influenza vaccine market. FluGen is actively advancing a valuable product pipeline that provides the company with ...

Vaxine Pty Ltd

Established in 2002, Vaxine is an Australian-based biotechnology company specialising in vaccine development. Lead products in clinical trials include vaccines for seasonal and pandemic influenza (including 2009 H1N1 swine flu), Japanese encephalitis, hepatitis B, and bee sting allergy.

Relevant

PaxVax, Inc.

PaxVax is a privately held company committed to developing better vaccines to better the world. Established in 2007, PaxVax has a clinical-stage product portfolio, including a cholera vaccine entering Phase 3 and a pandemic H5N1 influenza vaccine entering Phase 2. The company also has vaccines in development for HIV and anthrax under R&D contracts with NIH...

PaxVax Corporation

PaxVax is a privately held company established in 2007 to develop and commercialize innovative and socially responsible vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine entering Phase 3 and a pandemic H5N1 influenza vaccine entering Phase 2. The company also has vaccines in development for HIV...

CSL Biotherapies

CSL Biotherapies has an initial contract worth $180 million to deliver bulk H1N1 vaccine antigen to the U.S. Health and Human Services Department (HHS), with an option for filling and packaging services out of CSL’s Kankakee, Illinois and Marburg, Germany facilities. These facilities have the capability to produce seasonal and pandemic influenza vacci...

PaxVax Inc

PaxVax is a privately held company established in 2007 to develop and commercialize innovative vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine that recently initiated Phase 3 clinical trials and a pandemic H5N1 influenza vaccine entering Phase 2 clinical trials. The company also has vaccines ...

AlphaVax, Inc

AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease an...

BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Flu is the most common infectious disease, caused by countless flu strains, as the virus mutates unpredictably and frequently. Currently, seasonal flu vaccines are re-formulated each year a...

PaxVax Inc.

PaxVax is a privately held specialty vaccine company founded in 2007. PaxVax is focused on traveler vaccines with an emerging pipeline in biodefense coupled with a social mission to ensure global access to its vaccines. PaxVax’s clinical-stage product portfolio includes an oral, single-dose cholera vaccine in Phase 3 clinical trials, a pandemic H5N1 i...

Vivaldi Biosciences Inc.

Vivaldi Biosciences is developing live attenuated influenza vaccines (LAIVs) with the potential for increased effectiveness in the prevention of emerging pandemic influenza and seasonal influenza. Vivaldi’s LAIVs are designed using proprietary reverse genetics and plasmid rescue technologies to truncate the influenza NS1 gene. The unique method of att...

Inviragen, Inc. and PharmaJet, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Iomai

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, en...

Inviragen, Inc. and Duke-NUS

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease, chikungunya and Japanese encephalitis which affect millions of individuals in Asia. Vaccines in ...

Indian Immunologicals Limited

Indian Immunologicals Ltd (IIL) is a wholly owned subsidiary of National Dairy Development Board, established in 1983. IIL's plant at Hyderabad is built in collaboration with Wellcome Foundation of U.K. In addition to Foot and Mouth Disease (FMD) vaccine under the flagship brand name "Raksha", IIL also produces a range of other veterinary vaccines such as anti-rabies vaccine, Thileriosis vaccine, ...

Pevion Biotech AG

Pevion Biotech AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet medical needs based on its clinically and commercially validated virosome technology. Its proprietary clinical pipeline includes a first-in-class candidiasis vaccine. A clinical stage malaria vaccine candidate has been successfully out-licensed, and the Company’s technology has been o...

Inviragen, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer. Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination. HspC...


More From BioPortfolio on "Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks